Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2026Transplantation and Cellular Therapy

High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSagar MunjalMAMuneer H. AbidiJPJeremy Pantin

Discussion

Loading...

Member takes

Overview

High-dose cryopreserved bone marrow may reduce relapse rates in HLA-mismatched transplantation, implying better donor outcomes.

Key Points

  • High-dose cryopreserved bone marrow significantly reduces relapse rates in HLA-mismatched allogeneic transplantation.
  • At Day 180 post-transplant, early indicators show improved patient outcomes with this approach.
  • Observational analysis of patients receiving cryopreserved bone marrow demonstrates its promising effects on relapse.
  • These findings highlight the potential benefits of enhanced donor selection processes for improved transplant success.

Cite This Study

Munjal et al. (2026) studied this question.

synapsesocial.com/papers/69a760dcc6e9836116a2dfddhttps://doi.org/10.1016/j.jtct.2025.12.299
View Full Paper
Ask AI
Bookmark
Share